Convincing evidence for the efficacy of adenovirus-mediated IFN delivery is the success of the phase III CT of the drug Nadofaragene firadenovec for bladder cancer, where local delivery of IFNA2B via an adenovirus achieved high efficacy rates: complete remission was achieved in half of the patients (53%), and nearly a quarter (24%) maintained a response for 12 months. Here, IFNA2 is linked to urinary bladder cancer.